following a resubmission:
degarelix (Firmagon®) is accepted for use within NHS Scotland.
Indication under review: degarelix is a gonadotropin-releasing hormone (GnRH) antagonist indicated for the treatment of adult male patients with advanced hormone-dependent prostate cancer.
In one study that included patients with all stages of prostate cancer, degarelix was shown to be non-inferior to a luteinising hormone releasing hormone (LHRH) agonist in suppressing testosterone levels over a one year treatment period without an initial testosterone flare.
This SMC advice takes account of the benefits of a patient access scheme (PAS) that improves the cost-effectiveness of degarelix. This SMC advice is contingent upon the continuing availability of the patient access scheme in NHS Scotland.
Download detailed advice148KB (PDF)
Medicine details
- Medicine name:
- degarelix (Firmagon)
- SMC ID:
- 560/09
- Indication:
- for the treatment of adult male patients with advanced hormone-dependent prostate cancer.
- Pharmaceutical company
- Ferring Pharmaceuticals Ltd
- BNF chapter
- Malignant disease and immunosuppression
- Submission type
- Resubmission
- Status
- Accepted
- Date advice published
- 17 January 2011